Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. LFMD
LFMD logo

LFMD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy LifeMD Inc (LFMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.910
1 Day change
25.32%
52 Week Range
15.840
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

LifeMD Inc (LFMD) is not a strong buy at this moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the technical indicators show some positive momentum, the lack of significant trading trends, weak financial performance, and absence of strong catalysts make it a hold rather than a buy.

Technical Analysis

The MACD histogram is positive at 0.0568 and expanding, indicating bullish momentum. RSI is neutral at 58.261, and moving averages are converging, suggesting no clear trend. The stock is trading near resistance levels (R1: 3.082), with support at 2.62. Overall, the technical indicators are moderately positive but not strong enough for a decisive buy signal.

Options Data

Bullish
Open Interest Put-Call Ratio
Neutral
Option Volume Put-Call Ratio

The low put-call open interest ratio (0.1) indicates bullish sentiment, but the option volume put-call ratio (1.05) suggests a slight bearish sentiment in recent trading. Implied volatility is high at 111.86, with an IV percentile of 93.63, indicating elevated uncertainty.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
9

Positive Catalysts

  • The MACD is expanding positively, and the stock has a 50% chance of slight gains in the next week. Hedge funds and insiders are neutral, which avoids negative pressure.

Neutral/Negative Catalysts

  • No recent news or significant trading trends. Financial performance shows declining net income (-15.67% YoY) and EPS (-23.08% YoY). Gross margin has also dropped by 3.20% YoY. The stock has a higher probability of declining (-1.33%) over the next month. No recent congress trading data or influential figure activity.

Financial Performance

In Q3 2025, revenue increased by 12.95% YoY to $60.17M, but net income dropped by 15.67% YoY to -$4.58M. EPS declined by 23.08% YoY to -0.1, and gross margin fell by 3.20% YoY to 87.69%. The financials indicate revenue growth but worsening profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes is available for LFMD at this time.

Wall Street analysts forecast LFMD stock price to rise
7 Analyst Rating
Wall Street analysts forecast LFMD stock price to rise
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.120
sliders
Low
6
Averages
9.67
High
15
Current: 3.120
sliders
Low
6
Averages
9.67
High
15
H.C. Wainwright
Yi Chen
Buy
downgrade
$13 -> $9
AI Analysis
2025-11-19
Reason
H.C. Wainwright
Yi Chen
Price Target
$13 -> $9
AI Analysis
2025-11-19
downgrade
Buy
Reason
H.C. Wainwright analyst Yi Chen lowered the firm's price target on LifeMD to $9 from $13 and keeps a Buy rating on the shares following a top- and bottom-line miss in Q3. LifeMD, which is now a pure-play telehealth and pharmacy platform after the company divested its majority ownership in WorkSimpli, updated its 2025 total revenue guidance and the firm adjusted its projections accordingly, the analyst noted.
KeyBanc
Scott Schoenhaus
Overweight
downgrade
$12 -> $8
2025-11-19
Reason
KeyBanc
Scott Schoenhaus
Price Target
$12 -> $8
2025-11-19
downgrade
Overweight
Reason
KeyBanc analyst Scott Schoenhaus lowered the firm's price target on LifeMD (LFMD) to $8 from $12 and keeps an Overweight rating on the shares. The firm notes LifeMD is being impacted by low-cost compounders despite the FDA outlawing the practice earlier this year. However, KeyBanc expects cash prices for brand-name GLP-1s to continue to come down as well as stricter enforcement against compounders in FY26, which should benefit LifeMD due to its partnerships with Eli Lilly (LLY) and Novo (NVO). The firm also expects the launch of oral Wegovy in early FY26 to drive higher weight management subscribers.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LFMD
Unlock Now

People Also Watch